ArticleThe Journal of infectious diseases2025
Cervicovaginal Secretions in Young Women With Bacterial Vaginosis Enhance HIV Infection.
Article in The Journal of infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Anaerobe-Driven Inflammation and Epithelial Barrier Disruption in Genital HIV Acquisition.American journal of reproductive immunology (New York, N.Y. : 1989) · 2026Review
- Phage therapy for treatment of bacterial vaginosis.Archives of microbiology · 2026Review
- No change in key HIV target cell markers following initiation of three progestin-based hormonal contraception methods: findings from the CHIME study.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundBacterial vaginosis (BV) is a major health problem associated with increased HIV risk. To explore underlying mechanisms, we assessed the cervicovaginal mucosal immune environment before and after metronidazole treatment in women with BV and healthy controls.
methodsWomen with BV diagnosed clinically by Amsel criteria were treated with oral or intravaginal metronidazole. Vaginal swabs and cervicovaginal lavage (CVL) were obtained at enrollment and approximately 2 and 4 weeks later for assessment of immune mediators, antiviral activity, and 16-second rRNA gene sequencing. Healthy controls had sampling at enrollment and 4 weeks.
resultsVaginal pH, Nugent score, Shannon diversity index, and vaginal community state types differed significantly at enrollment between women with clinical BV (n = 19) and controls (n = 13, P < .001). BV cases had significantly higher CVL IL-1α and TNF-α but lower IgG at enrollment as compared with controls, which improved following treatment. Similar results were observed if participants with discordant molecular results (n = 3) were excluded. Most notably, CVL from BV cases enhanced, whereas control CVL inhibited, HIV infection of cells relative to buffer (mean ± SD, 138.4% ± 109.8% vs 30.9% ± 37.9%; P = .001). There was a transient reduction in HIV enhancement following treatment, which was not sustained. Enhancement correlated with community state types and markers of dysbiosis. Specifically, decreases in lactobacilli and increases in Prevotella, Dialister micraerophilus, and Peptoniphilus lacrimalis were associated with enhancement.
conclusionsThese findings provide a potential mechanistic link that may contribute to the increased risk of HIV in association with BV, and they highlight the importance of early diagnosis and improved treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.